Your browser doesn't support javascript.
loading
Research update of Tolicizumab in the treatment of juvenile idiopathic arthritis / 中华实用儿科临床杂志
Chinese Journal of Applied Clinical Pediatrics ; (24): 1604-1607, 2015.
Artigo em Chinês | WPRIM | ID: wpr-480567
ABSTRACT
Tocilizumab is a recombinant humanized monoclonal antibody against interleukin(IL)- 6 receptor (IL - 6R). It can prevent IL - 6 from binding to membrane - bound or soluble IL - 6R,thus blocking IL - 6 mediated signal transduction,and clinically alleviating inflammation and joint destruction in rheumatoid arthritis(RA). Both in the American and European Union,intravenous Tocilizumab has been approved for the treatment of both systemic juve-nile idiopathic arthritis(sJIA)and polyarticular JIA(pJIA)in patients aged ﹥ 2 years old. The approval was based on the favorable results from 2 randomized,double - blind,placebo - controlled,multinational,phase Ⅲ trials conducted in patients aged 2 - 17 years old with active sJIA or pJIA. Tocilizumab was generally well tolerated in patients with sJIA and pJIA. The most frequently reported adverse events in Tocilizumab recipients were infections,neutropenia,impaired liver function,etc.

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Ensaio Clínico Controlado Idioma: Chinês Revista: Chinese Journal of Applied Clinical Pediatrics Ano de publicação: 2015 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Ensaio Clínico Controlado Idioma: Chinês Revista: Chinese Journal of Applied Clinical Pediatrics Ano de publicação: 2015 Tipo de documento: Artigo